Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.90 |
| ▸ | JAK1 | P23458 | 20/20 | 0.90 |
| ▸ | TYK2 | P29597 | 20/20 | 0.90 |
| ▸ | JAK3 | P52333 | 12/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23584394 | 1.00 | JAK2 (0.90) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757106 | 1.00 | JAK2 (0.90) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757020 | 1.00 | JAK2 (0.90) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757000 | 0.95 | JAK2 (1.00) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757090 | 0.95 | JAK2 (1.00) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757111 | 0.95 | JAK2 (1.00) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757015 | 0.92 | JAK2 (0.83) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757058 | 0.92 | JAK2 (0.83) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL21757170 | 0.92 | JAK2 (0.83) | JAK2JAK1TYK2JAK3CYP2C19 | |
| SCHEMBL24742739 | 0.91 | JAK2 (0.81) | JAK2JAK1TYK2JAK3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105214-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | Zhuhai United Laboratories Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | JAK2 2/4885JAK1 1/4885TYK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.